Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2025
EGFR-mutated NSCLC is a distinct subtype that responds well to targeted therapies. Neoadjuvant targeted therapy aims to downstage tumors and improve surgical outcomes, but the prognostic role of residual viable tumor (RVT) remains unclear. This retrospective study examines the association between RVT and survival outcomes. The findings will further validate the importance of RVT as a surrogate.
Epistemonikos ID: fe3704dbca21999d9d66f2812ff30c88f392dc4a
First added on: Feb 01, 2025